The research explores the relationship between
abnormal blood and lymphatic vessel growth and human diseases, particularly
eye conditions. It suggests that substances which can inhibit these processes might offer a promising treatment for such diseases. The study utilized both laboratory and animal models to evaluate angiogenesis and lymphangiogenesis under conditions of
VEGF stimulation or hypoxia in endothelial and retinal cells.
The key finding was that an imidazole-based compound, referred to as
LCB54-0009, effectively prevented the formation of blood vessels in VEGF-stimulated HUVECs without causing cell damage. When injected into the eyes of mice and rats, it reduced
abnormal blood vessel growth and vascular permeability in conditions mimicking
retinopathy. Additionally, when applied to the cornea, it mitigated
inflammation and related blood and lymph vessel growth in both mice and rats.
The compound's therapeutic effects are believed to be linked to its impact on
HIF-1α protein stability and the redox sensitivity of HIF-1α/
NF-κB, along with its antioxidant properties. It also suppressed the expression of
angiopoietin-2 under hypoxic conditions and hindered VEGF-induced
VEGFR-2 activation and related signaling pathways. This resulted in a decrease in pro-angiogenic and pro-inflammatory factors and an increase in anti-angiogenic factors.
In conclusion, the study posits that LCB54-0009 could be a viable candidate for therapeutic intervention against pathological blood and lymphatic vessel growth, mediated through HIF-1α-angiopoietin-2 expression and VEGFR-2 activation.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

Click on the image below to go directly to the Translational Medicine search interface.
